FY2025 · ended Dec 31, 2025 · Revenue $14.20M, +29.1% YoY · Filed Mar 12, 2026
Opus Genetics, Inc. (IRD) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $14.2 million and a net loss of $49.6 million. As of Jun 30, 2026 it held $88.8 million in cash and investments and $35.3 million in total debt.
Revenue (TTM)
$9.86M
-36.1% vs year-ago TTM
Net income (TTM)
$-107.61M
-84.7% vs year-ago TTM
Operating cash flow (TTM)
$-40.67M
-27.8% vs year-ago TTM
Free cash flow
$-6.80M
EPS (TTM)
$-1.29
+14.9% vs year-ago TTM
Dividend per share
None
Shares outstanding
71.15M
+56.4% vs prior year
Net cash
$53.53M
as of Jun 30, 2026
Operating margin
-513.5%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IRD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1228627
- Former names
- Ocuphire Pharma, Inc. (until Oct 22, 2024); REXAHN PHARMACEUTICALS, INC. (until Nov 9, 2020); CORPORATE ROAD SHOW DOT COM INC (until Apr 29, 2005); FERRARO FRANK (until Apr 29, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $14.2M | $11.0M | $19.0M | $39.9M | $589,000 |
| Operating income | -$38.6M | -$62.1M | -$10.6M | $18.2M | -$22.7M |
| Net income | -$49.6M | -$57.5M | -$10.0M | $17.9M | -$56.7M |
| Diluted EPS | -$0.80 | -$2.15 | -$0.46 | $0.87 | -$3.82 |
| Operating cash flow | -$35.3M | -$25.6M | -$1.1M | $14.3M | -$19.4M |
| Total assets | $50.2M | $36.9M | $53.9M | $49.0M | $26.1M |
| Total liabilities | $34.9M | $11.3M | $4.0M | $2.8M | $3.9M |
| Stockholders' equity | $15.3M | $6.7M | $49.9M | $46.2M | $22.2M |
| Cash and investments | $45.1M | $30.3M | $50.5M | $42.7M | $219,000 |
| Total debt | $1.1M | — | — | $0 | $538,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 21, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 15, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 11, 2026 | Sep 11, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 9, 2026 | Sep 9, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
All 1001 Opus Genetics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.